Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio para evaluar Imetelstat en pacientes con SMD de alto riesgo o LMA que fallan en la terapia basada en HMA (IMpress)

10 de septiembre de 2026 actualizado por: GCP-Service International West GmbH

Un estudio de fase II que evalúa la eficacia y la seguridad de imetelstat en pacientes con síndromes mielodisplásicos HR o AML que fallan en la terapia basada en HMA

The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

46

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Düsseldorf, Alemania
        • Marien Hospital Düsseldorf
      • Jena, Alemania
        • Universität Jena, Medizinische Fakultät
      • Leipzig, Alemania
        • Universität Leipzig, Medizinische Fakultät
      • München, Alemania
        • Klinikum rechts der Isar
      • Adelaide, Australia
        • Royal Adelaide Hospital
      • Brisbane, Australia
        • Royal Brisbane and Women's Hospitals
      • Nedlands, Australia
        • Linear Clinical Research
      • Nantes, Francia
        • CHU Nantes - Hôtel Dieu
      • Nice, Francia
        • Hôpital Archet 1
      • Paris, Francia
        • Hôpital Saint-Louis
      • Toulouse, Francia
        • CHU de Toulouse

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Signed written informed consent
  • Male and female ≥ 18 years at the first screening
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Initial diagnosis of AML or MDS according to WHO (World Health Organization) 2016 classification
  • At least one cytopenia
  • Failure to achieve complete or partial response or hematological improvement observed after at least six azacitidine monotherapy or four decitabine monotherapy based 4-week treatment cycles administered during the past two years OR Failure to achieve complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least six (azacitidine) or four (decitabine) based 4-week treatment cycles administered during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Intolerance to treatment with HMA-based therapy during the past two years
  • Not eligible for allogeneic stem cell transplantation
  • ≥ 5% bone marrow blasts at screening
  • Off all other treatments for AML/MDS for at least 14 days; granulocyte colony-stimulating factor (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Biochemical laboratory test values must be within the defined limits.
  • Availability of blood counts and transfusion events for previous 16 weeks
  • Women of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies. For females, these restrictions apply for 3 months after the end of dosing.
  • A woman of childbearing potential must have a negative serum or urine pregnancy test at screening and agree to be tested on day 1 of every cycle and at End of Treatment (EOT)
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control. For males, these restrictions apply for 3 months after the end of dosing
  • Patients who are relapsed or refractory to, or not eligible for, therapy with approved and available FLT3 (FMS-like tyrosine kinase 3) or IDH1/IDH2 (Isocitrate dehydrogenase) inhibitors or other approved targeted therapies.

Exclusion Criteria:

  • Chemotherapy within the 14 days prior to the first dose of imetelstat being administered (other than hydroxyurea)
  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients (refer to the Investigators Brochure (IB))
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days prior to day 1 of Cycle 1
  • Prior treatment with imetelstat
  • Prior history of intensive chemotherapy or hematopoietic stem cell transplant
  • Major surgery within 4 weeks prior to day 1 of Cycle 1 (excluding the placement of vascular access and other minor surgical procedures)
  • Diagnosed or treated for malignancy other than MDS or AML, except:

Malignancy treated with curative intent and with no known active disease present for 3 years before day 1 of Cycle 1 Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease

  • Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of day 1 of Cycle 1, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
  • Known history of human immunodeficiency virus (HIV) or any uncontrolled active systemic infection requiring IV antibiotics
  • Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), or known acute or chronic liver disease including cirrhosis
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the participant 's safety, interfere with the imetelstat metabolism, or put the study outcomes at undue risk; Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Females who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 3 months after the end of dosing
  • Participant is a man who plans to father a child while enrolled in this study or within 3 months after the end of dosing
  • Other:

Participant is in custody by order of an authority or a court of law Participation in another interventional clinical study within the last 3 months prior to signing the Informed consent form (ICF) or simultaneous participation in other interventional clinical studies Previous assignment to treatment during this study Close affiliation with the investigator (e.g., a close relative) or persons working at the study site Participant is an employee of the sponsor or involved Contract Research Organization (CRO) Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the Participant's safety

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Imetelstat de un solo brazo

Intravenous injection

Otros nombres:
  • GRN163L

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Hematological Response Rate of Participants After Treatment With Imetelstat
Periodo de tiempo: Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders.

The response rate is calculated as number of responders divided by the number of all participants of the analysis set.

Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)
Periodo de tiempo: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Treatment Duration (Days)
Periodo de tiempo: From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.

The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.

From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.
Treatment Compliance
Periodo de tiempo: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Percentage of study-drug doses received relative to the number of doses planned per protocol.

Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Cumulative Dose (mg)
Periodo de tiempo: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form).

Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Uwe Platzbecker, MD, Universitätsklinikum Leipzig

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de junio de 2023

Finalización primaria (Actual)

27 de marzo de 2025

Finalización del estudio (Actual)

30 de septiembre de 2025

Fechas de registro del estudio

Enviado por primera vez

13 de octubre de 2022

Primero enviado que cumplió con los criterios de control de calidad

13 de octubre de 2022

Publicado por primera vez (Actual)

17 de octubre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IMpress_001

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .